Available online on 15 Jun, 2025 at https://ijdra.com/index.php/journal
International Journal of Drug Regulatory Affairs
Published by Diva Enterprises Pvt. Ltd., New Delhi
Associated with RAPS & Delhi Pharmaceutical Sciences & Research University

Review Article

Open Access

Medical Device Regulations in the US, Europe and India: A Boon or a Barrier for the Pharmaceutical Industry?

Divyadarshini Rajeshkumar[a], Sowmya Cherukuri[*,b]

[a]*Department of Pharmaceutical Regulatory Affairs, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai – 600116*

[b*]*Assistant Professor, Department of Pharmaceutics, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai – 600116*

Abstract

The medical device business, which offers cutting-edge instruments for diagnosis, monitoring, and treatment, is essential to the advancement of global healthcare. However, there are both opportunities and constraints for pharmaceutical companies due to the large regional variations in the regulatory environments controlling these devices. With an emphasis on post-market surveillance, approval processes, clinical evaluation standards, and device categorization, this analysis critically analyzes and contrasts the regulatory regimes of the US, EU, and India. Although strict laws in these areas are intended to protect patient safety, device effectiveness, and quality control, they frequently impact small and medium-sized businesses by lengthening development schedules, increasing compliance costs, and creating hurdles to market access. Additionally, covered are recent changes and projects meant to align international standards, integrate cutting-edge technology, and improve interagency cooperation. The study concludes by assessing whether these rules serve as a regulatory bottleneck that prevents timely access to life-saving technologies or as a catalyst for innovation and global competitiveness.

Conclusion: The review emphasizes the necessity for a well-rounded regulatory strategy that maintains safety without impeding advancements in the interface between pharmaceuticals and medical devices.

Keywords: Medical device, Regulatory pathways, US FDA, Medical Device Regulation (MDR), CDSCO, EUDAMED (European Database on Medical Devices)

Article Info: Received 19 May 2025; Review Completed 07 Jun 2024; Accepted 11 Jun 2025

Cite this article as:
Rajeshkumar D, Cherukuri S. Medical Device Regulations in the US, Europe and India: A Boon or a Barrier for the Pharmaceutical Industry?. Int. J. Drug Reg. Affairs [Internet]. 2025 Jun 15 [cited 2025 Jun 15]; 13(2):81-88. Available from:
http://ijdra.com/index.php/journal/article/view/765

DOI: https://doi.org/10.22270/ijdra.v13i2.765
*Corresponding author

1. Introduction

A vital part of the global healthcare sector, the medical device manufacturing industry is dedicated to the development, manufacture, and sale of a broad range of equipment intended to identify, prevent, monitor, and treat medical conditions. This industry produces a wide range of goods, from basic tools like tongue depressors to sophisticated devices like pacemakers and imaging equipment. US is considered as the home for the biggest medical device business in the world, with exports expected to reach over $103 billion by 2023. (1) In this field, items, equipment, instruments, or technologies are used to either prevent, detect, or cure diseases or illnesses, or to specify, measure, repair, rectify, or change the shape or function of the body in order to achieve a medical goal. Some of the processes in the manufacturing process include design, prototyping, material selection, quality control, and government compliance. New manufacturing techniques including injection molding, CNC machining and additive manufacture (3D printing) are frequently used to attain accuracy and dependability for medical application.(2) Due to the importance of medical devices, various procedures in manufacturing the medical device should comply with the stringent regulations to assure the safety and efficacy of the devices. Regulatory agencies like the USFDA are the authoritative persons for regulating and approval of medical devices thereby make sure that certain procedures are followed throughout the product's life cycle. The production of medical device is famous for being a continually innovative industry, driven by technological developments and a commitment to better patient outcomes. The companies in this sector invest heavily in R&D in an attempt to fulfill unmet medical needs and enhance healthcare everywhere. Statistics from the medical equipment industry globally: In the US alone, there are approximately 9,009 medical device manufacturing firms, (3) whereas in the EU, there are more

than 37,000 medical technology firms.(4) India has approximately 800 small-scale medical device makers.(5)

2. Objectives

The aim of this review article is to analyze and critically assess the legal frameworks that govern medical devices in the US, EU, and India, focusing on the implications for the pharmaceutical industry. This study digs into the whole setup from the way approval schedules, device classifications, and even the post-market watch come together to show that rules can sometimes help, and at other times really hold back firms aiming to roll out new medical equipment. It also spells out, in a somewhat offbeat way, the kinds of hassles companies face when dealing with local law quirks, and it tosses around a few ideas on how to manage these mixed-up regulatory setups. In most cases, the work wraps up by weighing if these mandates truly drive innovation, keep patients safe, and ease the path into global markets or if, really, they just add another barrier on the way.

3. Overview of Regulatory Framework:

3.1 United States: The hub of overseeing medical device rules is usually the Center for Devices and Radiological Health (CDRH) a part of the Food and Drug Administration (FDA) that pretty much takes on the regulatory duties.

a) Regulatory Paths:

- 510(k): If a product ends up being pretty much on par with an item already in circulation, manufacturers usually go with a premarket notification approach—a sort of quick heads-up to regulators rather than a long, drawn-out review process.
- Premarket Approval (PMA): For Class III medical devices which involves high-risk technologies scientific review should be performed.
- De Novo Classification: For new devices that are not comparable to existing products and do not fit into any of the current regulatory categories.
- Relevant laws include the 1976 Medical Device Amendments and the Federal Drug, Cosmetic, and Food Act (FD&C Act).
- The Quality System Regulation, or CFR Part 820, contains guidelines for the production and administration of medical devices.(6)

3.2 European Union (EU): The European Medicines Agency (EMA) is in charge of regulating medical devices, and Notified Bodies help to approve compliance assessments.

a) Rules:

- Safety, clinical assessment, and post-market surveillance are the main focuses of the Medical Device Regulation (MDR 2017/745), which serves as the basis for medical device regulation.
- The In Vitro Diagnostic Regulation (IVDR) governs in vitro diagnostic equipment in Europe.
- By following the CE certification process, a gadget is guaranteed to comply with all applicable EU rules.
- The makers must conduct clinical testing and third-party audits by Notified Bodies as part of the compliance assessment process.(7)

3.3 India: The regulatory authority of India (CDSCO) is responsible for overseeing and authorizing medical devices throughout India

a) Rules:

- Medical Device Regulations (MDR) 2017: regulates the approval and market entry of medical devices and implements risk classification based on international criteria.

b) The approval process:

- Risk-Based Classification: Devices are categorized under Class A, B, C, and D based on the level of risk.
- Import Registration: Foreign manufacturers are required to register their equipment with CDSCO prior to importing into India.
- Domestic Licensing: To sell medical equipment in India, manufacturers need a license.(8)

4. The Importance of Understanding Regional Regulations:

Pharmaceutical corporations attempting to navigate the complexities of global marketplaces need to be cognizant of the legislation regarding medical devices in the US, Europe, and India. Various regulatory frameworks in various regions affect product development, approval processes, market access, and overall business strategy.(9)

4.1 US:

In the US, medical devices are controlled by the FDA. The FDA categorizes devices into three risk classes: Class I (low risk), Class II (moderate risk), and Class III (high risk). It is helpful to understand these classes when selecting the optimal regulatory pathway, which affects time-to-market and development cost. For example, compared to Class III devices, which would need more thorough clinical trials, Class I devices frequently need fewer regulatory constraints.(10)

4.2 European Union:

Medical equipment must first have the CE mark in order to be sold under an EU system. Several compliance assessment techniques are used in this process, depending on the device's classification.(11) Since the Medical Device Regulation (MDR) came into effect in 2021, the requisite for clinical data and post- marketing surveillance has been increased.(12)The main goal of these adjustments is to improve patient safety, but it also increased the time and cost needed to bring the product into market. For

example, it took around twelve months for a new technology to reach the US market, but now it takes five or six years.

4.3 India:

The CDSCO who is in-charge of various approval procedures in India regulates the changing medical device laws. The Medical Device Regulations (MDR) 2017 includes risk-based classification system with an effort to conform with the global standards. Because of such alignment with international standards, medical devices that are approved in other countries can be imported easily. However, manufacturers must meet Indias's specific regulatory requirements. The manufacturers should understand these regulations clearly to expand their business in the Indian market.(13)

5. Recent Developments

5.1 US: In 2023, the USFDA's CDRH (Centre for Medical Devices and Radiological Health) approved 36 original Premarket approval (PMA) application and 2,180 Premarket approval supplements. This made a great contribution to around 5,807 marketing submission authorized during 2023 (14)

5.2 European Union: The Medical Device Regulation (MDR) of the European Union, which came into effect in April 2017 which modified the European legal framework for medical devices and placed various additional duties on the state responsible authorities and the European Medicines Agency (EMA) (14)

5.3 India: CDSCO has introduced some registration system for medical devices that are non- notified, under the Medical Device Rules, 2017. A system of 18-month voluntary registration period allows the manufacturers and the importers to register the medical devices without requiring a license. Such system is followed by a 24-months mandatory registration phase, where the registration becomes compulsory before transitioning of full licensing. After 24 months a formal license is required for manufacturing or importing the medical devices.(15)

6. Amendments:

6.1 United States (US):

2023 Draft Update to Pulse Oximeters Guidance: New suggestions for enhancing pulse oximeter accuracy, particularly in relation to various skin tones.(16) To increase efficiency, reduce regulatory hurdles, and harmonize international standards, 21 CFR Part 820 is expected to be changed to comply with ISO 13485:2016, a worldwide medical device quality management system standard.(17)

Amendment: New recommendations to improve device performance across a range of demographics and lessen health inequalities.

6.2 EU:

a) EU Regulation 2024/1860-2024:

Amendment: Phased deployment of EUDAMED (European Database on Medical Devices) and extended transition periods for specific IVDs.(18) Goal: Increase openness and speed up device tracing and post-market surveillance.

b) Regulation 2023/607-2023 of the EU

Amendment: MDR (EU) 2017/745's transition periods for medical devices—particularly Class I sterile/measuring devices—are prolonged.(19) Goal: Give manufacturers more time to adjust to MDR because of resource limitations and certification issues.

6.3 India:

The 2020 Medical Devices (Amendment) Regulations in India

Amendment: Modifications to the 2017 Medical Device Rules, such as updated classification schemes, new registration procedures, and risk-based regulatory routes.(8) The goal is to guarantee safety in compliance with international standards and improve regulatory oversight.

The 2023 Import License Requirement Amendment

Amendment: A mandatory import license will be required for Class A (Sterile/Measuring), B, C, and D devices as of October 1, 2023 (MD-14/15).(20)

Goal: Improve product quality and traceability for imported equipment.

7. Comparative Analysis of Medical Device Regulations in US, EU and India Focusing on Classification System, Approval Pathways, PMS and Vigilance Requirements, and Clinical Evaluation Requirements

7.1 The United States (US)

In the US, medical devices are divided into three groups according to their degree of risk:

- Class I: Low risk; Broadly regulated.
- Class II: Moderate risk; Controls are both broad and particular.
- Class III: High risk; Premarket approval and general controls are relevant. It establishes the approval requirements and regulatory oversight.(10)

a) Channels of Approval:

- 510(k) Premarket Notification: For goods that are nearly identical to already-available products.(21)
- Premarket Approval (PMA): For high-risk technologies that need more thorough clinical studies and scientific analysis.(22)

In the case of novel devices without a predicate, it is called "De Novo Classification." The pathway is determined by the device's classification and risk assessment.

b) Post-Marketing Monitoring and Vigilance Requirements:

Reporting Medical Devices (MDR): demands that negative events and defects in the equipment be reported. Certain devices require post-approval studies to make sure of their ongoing safety and effectiveness. Manufacturers

must monitor how the gadget is operating and report any safety concerns to the FDA. (23)



Figure 1. USFDA Medical device classification

c) Standards for Clinical Assessment: Before being approved, Class III high-risk devices must pass clinical studies. Clinical Data: To prove safety and efficacy, studies or trials are required. The FDA examines clinical data to guarantee the safety and efficacy of products.

7.2 European Union (EU)

a) Classification System:

In the EU, medical devices are divided into four classifications based on risk:

- Class I: Lowest level of danger.
- Class IIa: Moderate danger.
- Class IIb: Risky to moderate.
- Class III: Extremely dangerous.(24)

The process of evaluating compliance and the participation of Notified Bodies are determined by classification.



Figure 2. EU Medical device classification

b) Channels of Approval:

- Depending on the class, conformance assessment includes adding Notified Bodies for devices that pose a greater risk.
- CE Marking: Products must show that they comply with EU rules before they may be marketed in the EU.
- The process includes clinical examination, and clinical trials may be necessary.

c) Requirements for Vigilance and Surveillance after Marketing: PMS: Continuous assessment of the device's performance in the market is known as post-market surveillance, or PMS. The Vigilance System reports serious occurrences and remedial safety field activities to the relevant authorities. Manufacturers must adhere to PMS timetables and alert authorities to any problems.(24)

d) Standards for Clinical Assessment

Manufacturers must submit clinical data, gathered through clinical examination, to substantiate device claims. For many high-risk gadgets to be shown safe and effective, clinical research is necessary. The process of clinical evaluation continues for the duration of the device's life.

7.3 India

a) Classification system: Four risk-based classes are used to categorize medical equipment in India.

- Class A: Low risk.
- Class B: Low to moderate.
- Class C: Moderate to high risk.
- Class D: High risk (15)

The classification establishes regulatory expectations, approval processes, and post-marketing supervision.

b) Channels of Approval: Risk-Based rating: The approval procedure is impacted by the devices' risk level rating.
Prior to importation, foreign manufacturers are required to register their gadgets with CDSCO. (25) Manufacturing License: CDSCO must grant a license to domestic producers. The approval procedure includes post-market surveillance, clinical data reporting, and quality compliance.

c) Post-marketing surveillance and monitoring requirements:
After a product is approved, post-marketing surveillance is used to track its performance and report any negative incidents. Producers are required under the CDSCO

Vigilance System to report bad incidents, and investigations may be carried out. Post-marketing clinical studies are conducted on devices to confirm their security and performance.(26)



Figure 3. CDSCO Medical device classification

d) Standards for Clinical Assessment: Clinical studies are required to ascertain the efficacy and safety of high-risk technologies (Class C and D). For the application to be accepted, clinical data must be submitted with it. The CDSCO completely reviews the clinical data to ensure the safety standards of the medical devices.(26)

8. Impact of Current Regulations on Medical Devices

8.1 US:

The USFDA classifies the risk of each and every product which is a part or system of US rules. Increasing the price and approval time for the manufacturers is the outcome of FDA's strict rules, which focuses to ensure the safety and efficacy of the product. However, the original structure provided by these regulations help in introduction of conforming products into the market. The FDA's approach can provide difficulties for businesses looking to enter the market quickly, even while it is praised for its ability to ensure that stringent safety regulations are followed.

8.2 European Union:

The Medical Device Regulation (MDR), which went into effect in 2021, established stricter guidelines for device clearance, including improved clinical data and post-market surveillance. These steps have increased the cost and duration of product introduction, even though their goal was to improve patient safety. In the United States, for instance, it now takes five or six years instead of twelve months to commercialize new technologies. This type of regulatory environment can increase development costs and delay the release of new drugs, making it challenging for pharmaceutical companies, especially small ones, to navigate.

8.3 India:

India's medical device legislation has evolved over time, with the CDSCO overseeing the clearance process. To make the Medical Device Regulations (MDR) 2017 more aligned with global standards, a risk classification system was introduced. This alignment facilitates the entry of allowed products from other areas into the market, but manufacturers need to adhere to India's special regulatory requirements as well. It's essential that companies seeking to expand their market share in India understand these nuances.(27)

8.4 Positive Features

Enhanced Patient Protection: Harsher regulations, including the Medical Device Regulation (MDR) 2017/745 of the European Union, are designed to provide consumers with additional protection against safety and health risks.

Enhanced Product Quality: The MDR creates new standards for clinical research through demanding solid and reliable data. Clinical research performed by pharmaceutical firms is held to the same level of quality and safety as clinical trials.

8.5 Negative Features

The new EU medical device regulation is expected to lead to an extra 10% to 15% in research expenses for medical equipment, which will be transferred to customers in the form of increased sale prices.

Longer Time to Market: It now takes five or six years in Europe to take new products to market, rather than twelve months in the US. This difference may hinder innovation and make it harder for patients to gain access to innovative medical treatments.

Challenges for Small and Medium-Sized Enterprises (SMEs): The regulation increases the cost of developing and sustaining the product, which places SMEs, which dominate the medical device industries, under more financial risk.

9. Current Challenges and Future Objectives: The pharmaceutical industry is confronted with several challenges due to the evolving regulations relating to medical devices, both challenges and opportunities.

9.1 Current challenges:

- The most difficult part is probably negotiating the several worldwide regulatory frameworks that control the production, distribution, and research of pharmaceuticals. International approval of new modalities and production techniques might take years.
- More clinical evidence and documentation is required as a result of new regulations, changes, and guidance materials. Serious consequences for noncompliance can include FDA warning letters,

restrictions on marketing, product recalls, fines, and damage to a brand's reputation.

- Supply Chain Issues and Inflation: The industry has been plagued by issues with the supply chain and inflation, which have raised costs and decreased earnings. Changing vendors is more challenging due to regulatory restrictions.(28)

9.2 Future prospects:

- Harmonization of Regulations: Efforts are underway to harmonize worldwide regulatory systems in order to reduce complexity and facilitate compliance. This category includes efforts to harmonize standards across locations because they facilitate market access.
- Application of Advanced Technology: Two examples of cutting-edge technologies that are expected to transform regulatory processes are artificial intelligence and data analytics. Strong audit trails, better data submissions, and the creation of novel treatment modalities and device technologies are all possible with these technologies.
- Better Cooperation: To encourage a more transparent regulatory approach, it is expected that industry players and regulatory agencies will collaborate more closely. The industry and patients both gain from this coordination, which may introduce fast approval process and enable the development of novel medications.

Table 1. Comparison of Medical Device Regulations: US, EU and India

Parameter	United States (US)	European Union (EU)	India
Regulatory Authority	FDA – Center for Devices and Radiological Health (CDRH)	European Medicines Agency (EMA), Notified Bodies	Central Drugs Standard Control Organization (CDSCO)
Main Regulation(s)	FD&C Act, Medical Device Amendments 1976, 21 CFR Part 820	MDR 2017/745, IVDR	Medical Device Rules (MDR) 2017
Classification System	Class I (Low risk) Class II (Moderate risk) Class III (High risk)	Class I (Lowest risk) Class IIa (Moderate risk) Class IIb (Moderate–high risk) Class III (High risk)	Class A (Low risk) Class B (Low–moderate risk) Class C (Moderate–high risk) Class D (High risk)
Approval Pathways	-510(k) Premarket Notification -PMA (Premarket Approval) -De Novo Classification	- CE Marking -Notified Body involvement (Class IIa–III) -Clinical evaluation /trials required based on class	-Import registration (for foreign manufacturers) -Domestic manufacturing license -Risk-based approval process
Post-Market Surveillance (PMS) & Vigilance	Medical Device Reporting (MDR) system Post-approval studies required for certain devices	Vigilance System PMS plan mandatory Reports on serious incidents and field safety actions	CDSCO Vigilance System Post-marketing clinical studies Adverse event reporting and investigation
Clinical Evaluation Requirements	Mandatory for Class III devices Clinical data needed to support safety and efficacy	Clinical evaluation based on class Continuous assessment over device lifecycle	Required for Class C & D devices Clinical data submission mandatory for high-risk products
Recent Amendments	-Pulse Oximeters Guidance 2023 -21 CFR Part 820 to align with ISO 13485:2016	-Regulation 2024/1860: Phased EUDAMED, extended IVD transition -Regulation 2023/607: MDR transition extension	-2020 MDR Amendment: classification updates -2023 Import License Amendment: compulsory import license (Class A-D)
Challenges	High development cost Strict compliance requirements Slower market entry for SMEs	Increased research and compliance cost 5–6 years to market vs 1 year in US Harder for SMEs	Adherence to specific Indian requirements Need for clarity on evolving frameworks
Positive Impacts	Strong safety assurance Encourages quality products	Better patient protection Enhanced product quality	Aligned with global standards Easier import of globally approved devices
Negative Impacts	Slower approval timelines Cost-intensive compliance	High cost & delayed market access Innovation slowdown	Compulsory compliance despite global approval Regulatory adaptation needed

10. Conclusion

The implementation of new medical device regulations has undoubtedly had an impact on the pharmaceutical industry, both favorably and unfavorably. Nevertheless, there are complex regulations governing the integration of medical and technological devices. More rigorous clinical evaluation standards must be fulfilled as the environment evolves, which could result in longer approval times and higher operating costs. These considerations have led to greater pressure on pharmaceutical businesses, especially those who manufacture combination drugs. Nonetheless, the goal of these new regulations is to enhance the

functionality and security of medical devices. Since this will enhance patient outcomes, only high-quality, strictly regulated products should be permitted to reach the market. This may benefit the pharmaceutical industry by boosting patient tolerance and confidence. The limits also offer long-term benefits, such as encouraging innovation and opening up new markets, despite the possibility of short-term challenges. In the end, despite the complexity presented by these new medical device rules, the environment has become stronger, more secure, and more effective, which may open up new avenues for pharmaceutical businesses to develop and expand. How well the industry can take advantage of these opportunities while managing the resulting complexity will depend on its capacity to adjust to these regulatory changes. In conclusion, current medical device laws improve patient safety and product quality, but they also raise development costs, lengthen time to market, and provide small and medium-sized pharmaceutical enterprises new obstacles. Current medical device rules give the drug industry a great deal of headache, but the recent efforts toward harmonizing the rules, embracing new technologies, and enhancing coordination offer promising ways to overcome such challenges and advance healthcare innovation.

Acknowledgements

I would like to express my sincere gratitude to the editorial team and reviewers of the International Journal of Drug Regulatory Affairs for their valuable feedback and support throughout the review and publication process. Their constructive comments have significantly enhanced the quality of the article.

Financial Disclosure Statement:

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Reference

1. U.S. Department of Commerce. Select USA Medical Technology Industry [Internet]. Washington (DC): International Trade Administration; 2023 Feb 15 [cited 2025 May 07]. Available from: https://www.trade.gov/selectusa-medical-technology-industry
2. Xometry. 3D Printing in Medicine and Healthcare [Internet]. Gaithersburg (MD): Xometry Inc.; 2022 Nov 3 [cited 2025 May 07]. Available from: https://www.xometry.com/resources/3d-printing/3d-printing-in-medicine-and-healthcare/
3. IBISWorld. Medical Device Manufacturing in the US [Internet]. New York (NY): IBISWorld Inc.; 2023 Dec 21 [cited 2025 May 07]. Available from: https://www.ibisworld.com/united-states/number-of-businesses/medical-device-manufacturing/764/
4. Euractiv. It's time for Europe to harness the power of medical technology [Internet]. Brussels: Euractiv; 2023 Oct 9 [cited 2025 May 07]. Available from: https://www.euractiv.com/section/health-consumers/opinion/its-time-for-europe-to-harness-the-power-of-medical-technology/
5. Department of Pharmaceuticals. Medical Devices [Internet]. New Delhi: Government of India; 2023 Jan 25 [cited 2025 May 07]. Available from: https://pharma-dept.gov.in/medical-devices
6. USFDA, Overview of Device Regulation [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2019 Mar 18 [cited 2025 May 07]. Available from: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/overview-device-regulatio
7. EMA. Medical devices [Internet]. Amsterdam (Netherlands): EMA; 2022 Jul 10 [cited 2025 May 07]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices
8. Pharmabiz. Exploring regulatory challenges in global pharmaceutical market [Internet]. Mumbai: Pharmabiz. com; 2024 Aug 22 [cited 2025 May 07]. Available from: https://www.pharmabiz.com/NewsDetails.aspx?aid=173910&sid=9
9. USFDA, Classify Your Medical Device [Internet]. Silver Spring (MD): U.S. FDA; 2020 Jan 12 [cited 2025 May 07]. Available from: https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
10. CDSCO, Circulars [Internet]. New Delhi: CDSCO; 2023 Mar 3 [cited 2025 May 07]. Available from: https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Medical-Devices-Rules/
11. Emergo by UL. 2023 annual report from US FDA medical device regulatory division [Internet]. Austin (TX): Emergo; 2024 Jan 30 [cited 2025 May 07]. Available from: https://www.emergobyul.com/news/us-fda-cdrh-2023-annual-report-summary
12. CDSCO, Medical device & diagnostics [Internet]. New Delhi: CDSCO; 2022 Dec 12 [cited 2025 May 07]. Available from: https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/
13. USFDA, Quality Management System Regulation: Final Rule – FAQs [Internet]. Silver Spring (MD): U.S. FDA; 2024 Feb 2 [cited 2025 May 07]. Available from: https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked
14. EUR-Lex. Regulation - EU - 2024/1860 - EN [Internet]. Brussels: Publications Office of the EU; 2024 Apr 10 [cited 2025 May 07]. Available from: https://eur-lex.europa.eu/eli/reg/2024/1860/oj/eng
15. EUR-Lex. Regulation - 2023/607 - EN [Internet]. Brussels: Publications Office of the EU; 2023 Mar 15 [cited 2025 May 07]. Available from: https://eur-lex.europa.eu/eli/reg/2023/607/oj/eng
16. CDSCO, Imports & Registration [Internet]. New Delhi: CDSCO; 2023 Jul 10 [cited 2025 May 07]. Available from: https://cdsco.gov.in/opencms/opencms/en/Departments/Headquarters/imports/
17. USFDA, Premarket Notification 510(k) [Internet]. Silver Spring (MD): U.S. FDA; 2021 Oct 05 [cited 2025 May 07]. Available from:

https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
18. USFDA, Premarket Approval (PMA) [Internet]. Silver Spring (MD): U.S. FDA; 2020 Nov 19 [cited 2025 May 07]. Available from: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma
19. USFDA, Medical Device Reporting (MDR): How to Report Medical Device Problems [Internet]. Silver Spring (MD): U.S. FDA; 2022 Aug 01 [cited 2025 May 07]. Available from: https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems
20. EUR-Lex. Regulation - 2017/745 - EN - Medical Device Regulation [Internet]. Brussels: Publications Office of the EU; 2017 May 05 [cited 2025 May 07]. Available from: https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng
21. CDSCO, MD - Medical Devices [Internet]. New Delhi: CDSCO; 2023 Oct 20 [cited 2025 May 10]. Available from: https://cdscomdonline.gov.in/NewMedDev/Homepage
22. Manu M, Anand G. A review of medical device regulations in India, comparison with European Union and way-ahead. Perspect Clin Res. 2022 Jan;13(1):3–11.
23. Ladd ME. The Medical Device Regulation and its impact on device development and research in Germany. Z Med Phys. 2023 Nov;33(4):459–61.
24. French-Mowat E, Burnett J. How are medical devices regulated in the European Union? J R Soc Med. 2012 Apr 16;105(1_suppl):22–8.
25. Nüssler A. The new European Medical Device Regulation: Friend or foe for hospitals and patients? Injury. 2023 Oct;54:110907
26. Hao S, Dempsey K, Matos J, Cox CE, Rotemberg V, Gichoya JW, et al. Utility of Skin Tone on Pulse Oximetry in Critically Ill Patients: A Prospective Cohort Study. Crit Care Explor. 2024 Sep 13;6(9):e1133.
27. Pane J, Francisca RDC, Verhamme KMC, Orozco M, Viroux H, Rebollo I, et al. EU postmarket surveillance plans for medical devices. Pharmacoepidemiol Drug Saf. 2019 Sep 18;28(9):1155–65.
28. Patil GV, Basarkar GD. A Review on Approval and Registration Process of Medical Devices in Canada and India. Int J Drug Regul Aff. 2023 Dec 16;11(4):39–51.